UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact Name if Business Issuer as specified in its Charter)
(State or other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
(Address of principal executive offices, including zip code)
(Registrant’s telephone number including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 1 4a- 12 under the Exchange Act (17 CFR 240.1 4a- 12) |
| Pre-commencement communications pursuant to Rule 1 4d-2(b) under the Exchange Act (17 CFR 240.1 4d-2(b)) |
| Pre-commencement communications pursuant to Rule 1 3e-4(c) under the Exchange Act (17 CFR 240.1 3e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| OTCQB |
Item 8.01 Other Events.
On September 7, 2022, Bioxytran, Inc. (“Bioxytran” or the “Company”) registered, in India, a fully owned subsidiary, Pharmalectin India Private Limited, (the “Subsidiary”). The purpose of the Subsidiary is to be the sponsor of the Company’s clinical trials and commercialize the Company’s products, in India. The Subsidiary’s Certificate of Registration is filed as Exhibit 21.5 hereto.
In connection with the issuance of the above registration, the Company issued, on December 14, 2022, a press-release over GlobeNewswire, filed as Exhibit 99.1 hereto, under the title:
“Bioxytran Establishes Indian Subsidiary in Preparation of Commercialization”
On December 14, 2022, Bioxytran (the “Company”) released an updated Corporate Presentation explaining the current state of the Company’s pharmaceutical development. The presentation is attached hereto as Exhibit 99.2.
| 1 |
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit | ||
| Number | Description | |
| 21.5 | Certificate of Incorporation Foreign (Pharmalectin India Pvt Ltd) Subsidiary | |
| 99.1 | Press-release - Bioxytran Establishes Indian Subsidiary in Preparation of Commercialization, dated December 14, 2022. | |
| 99.2 | Bioxytran, Inc. Corporate Presentation, dated December 14, 2022 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| By: | /s/ David Platt | |
| Name: | Dr. David Platt | |
| Title: | President and Chief Executive Officer | |
| Dated: December 14, 2022 | ||
| 3 |